A note from the editor-in-chief

Given the historical tendency of clinicians to adopt a "one size fits all" approach to many clinical problems, we are beginning to see the influence of genomic medicine in changing this mindset. Assisted reproductive technologies (ARTs) are not only expensive but fraught with the risk of failure during any given cycle. Lazaros and colleagues have sought to refine their approach to treating patients selected for ART by looking at genetic variants, FSH Receptor 307 (T/A)/FSHR 680 (N/S) diplotypes, and ovarian response to FSH stimulation. After comparing women undergoing IVF/ICSI with women with at least one spontaneous pregnancy, they showed that higher sensitivity to FSH stimulation was more highly associated with the Thr307Ala/ Asn680Ser than with the two other variants identified.